"hivウイルス" の関連情報検索結果
WHO HIVResNet HIV drug resistance laboratory operational framework - World Health Organization (WHO)

WHO HIVResNet HIV drug resistance laboratory operational framework World Health Organization (WHO)
Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment - fda.gov

Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment fda.gov
A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces th...

Some children who start antiretrovirals very early may control HIV after stopping treatment - Aid...

Some children who start antiretrovirals very early may control HIV after stopping treatment Aidsmap
London patient remains HIV-free after 2.5 years off treatment - Aidsmap

London patient remains HIV-free after 2.5 years off treatment Aidsmap
Scientists use gene-edited stem cells to treat HIV — with mixed success - Nature

Scientists use gene-edited stem cells to treat HIV — with mixed success Nature
Nearly a third of babies with HIV given ART very soon after birth have no HIV antibodies two year...

Lenacapavir shows continued promise for first-line treatment and highly resistant HIV - Aidsmap

Lenacapavir shows continued promise for first-line treatment and highly resistant HIV Aidsmap
‘Molecular scissors’ successfully remove HIV genes from all tissues in infected monkeys - Aidsmap

‘Molecular scissors’ successfully remove HIV genes from all tissues in infected monkeys Aidsmap
Child with HIV maintains viral suppression for three years off treatment - Aidsmap

Child with HIV maintains viral suppression for three years off treatment Aidsmap
Sharing anti-HIV medication is common in rural Uganda - Aidsmap

Sharing anti-HIV medication is common in rural Uganda Aidsmap
New York woman is free of HIV 14 months after stem cell transplant - Aidsmap

New York woman is free of HIV 14 months after stem cell transplant Aidsmap
Barcelona woman controls HIV for over 15 years without treatment - Aidsmap

Barcelona woman controls HIV for over 15 years without treatment Aidsmap
São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatme...

São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatment Aidsmap
One person remains undetectable without HIV drugs almost four years after using an antibody-based...

After viral rebound, dolutegravir-based treatment more likely to suppress HIV - Aidsmap

After viral rebound, dolutegravir-based treatment more likely to suppress HIV Aidsmap
German man remains free of HIV nearly 10 years after stem cell transplant - Aidsmap

German man remains free of HIV nearly 10 years after stem cell transplant Aidsmap
People with HIV gain weight faster than HIV-negative people - Aidsmap

People with HIV gain weight faster than HIV-negative people Aidsmap
Oral lenacapavir can bridge gaps if injections must be missed - Aidsmap

Oral lenacapavir can bridge gaps if injections must be missed Aidsmap
Brazilian man in long-term HIV remission – without a stem cell transplant - Aidsmap

Brazilian man in long-term HIV remission – without a stem cell transplant Aidsmap
Long-acting capsid inhibitor GS-6207 confirms safety and antiviral activity - Aidsmap

Long-acting capsid inhibitor GS-6207 confirms safety and antiviral activity Aidsmap
The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance be...

Can U=U be used to reshape HIV programmes globally? - Aidsmap

New cases of multi-drug resistant HIV becoming rarer in Europe - Aidsmap

New cases of multi-drug resistant HIV becoming rarer in Europe Aidsmap
HIV incidence fell by three-quarters in Australian gay men, with strong association with treatmen...

The amber light: the World Health Organization’s position when an HIV viral load is “suppressed b...

Biktarvy combination pill may be most effective option for people with HIV and hepatitis B - Aidsmap

Biktarvy combination pill may be most effective option for people with HIV and hepatitis B Aidsmap
Have HIV-associated neurological disorders declined in people with HIV due to recent antiretrovir...

Earlier treatment and higher CD4 counts linked to smaller HIV reservoir - Aidsmap

Earlier treatment and higher CD4 counts linked to smaller HIV reservoir Aidsmap
Yes, the same life expectancy as HIV-negative people, but far fewer years in good health - Aidsmap

Yes, the same life expectancy as HIV-negative people, but far fewer years in good health Aidsmap
Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure - Aidsmap

Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure Aidsmap
At-home support after HIV diagnosis in Uganda helps people get on ART and stick with it - Aidsmap

At-home support after HIV diagnosis in Uganda helps people get on ART and stick with it Aidsmap
San Francisco shows that long-acting cabotegravir and rilpivirine may be feasible for people with...

Broadly neutralising antibodies may be partners for long-acting antiretrovirals - Aidsmap

Broadly neutralising antibodies may be partners for long-acting antiretrovirals Aidsmap
Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel? - Aidsmap

Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel? Aidsmap
High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis - ...

High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis ScienceDirect.com
Two PEP doses spaced a week apart protect monkeys from injected HIV; one dose might work in human...

Two PEP doses spaced a week apart protect monkeys from injected HIV; one dose might work in humans Aidsmap
Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing ...

HIV treatment in the womb helped five South African baby boys to stay undetectable off therapy - ...

HIV treatment in the womb helped five South African baby boys to stay undetectable off therapy Aidsmap
Black MSM are 60% less likely to have suppressed HIV than white men in Atlanta - Aidsmap

Black MSM are 60% less likely to have suppressed HIV than white men in Atlanta Aidsmap
Resistance testing does not improve viral suppression after first-line failure in South Africa an...

Reduced-drug treatment becoming common in Paris - Aidsmap

PD-1 inhibitor budigalimab may delay viral rebound - Aidsmap

More options for second-line treatment in children shown to be safe and effective - Aidsmap

More options for second-line treatment in children shown to be safe and effective Aidsmap
Four days on, three days off HIV treatment as effective as continuous therapy, French study finds...

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds Aidsmap
Experts shed light on coronavirus response and its implications for people with HIV - Aidsmap

Experts shed light on coronavirus response and its implications for people with HIV Aidsmap
Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe - Aidsmap

Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe Aidsmap
“If we don’t include women in trials, we are not protecting women” – dolutegravir in pregnant wom...

Point-of-care viral load testing improves treatment outcomes and retention in care - Aidsmap

Point-of-care viral load testing improves treatment outcomes and retention in care Aidsmap
Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up - Aidsmap

Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up Aidsmap
African studies show that lowering viral load in the community reduces HIV incidence, but is not ...

Fostemsavir salvage therapy continues to look good at 96 weeks - Aidsmap

Fostemsavir salvage therapy continues to look good at 96 weeks Aidsmap
Long-acting injectables might be administered every two months - Aidsmap

Long-acting injectables might be administered every two months Aidsmap
Islatravir plus doravirine maintains viral suppression for a year - Aidsmap

Islatravir plus doravirine maintains viral suppression for a year Aidsmap
Woman with HIV with low CD4 count remained positive on SARS-CoV-2 tests for over 5 months - Aidsmap

Woman with HIV with low CD4 count remained positive on SARS-CoV-2 tests for over 5 months Aidsmap
Who is at risk of injectable treatment failure? - Aidsmap

Adherence counselling reverses viral rebound on dolutegravir in 95% of cases - Aidsmap

Adherence counselling reverses viral rebound on dolutegravir in 95% of cases Aidsmap
Luc Montagnier, co-discoverer of HIV, dies aged 89 - BBC

Opportunistic infections remain common in people taking HIV treatment in Latin America - Aidsmap

Opportunistic infections remain common in people taking HIV treatment in Latin America Aidsmap
Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women - Aid...

Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women Aidsmap
Poor adherence associated with disruptive life events in young people living with HIV - Aidsmap

Poor adherence associated with disruptive life events in young people living with HIV Aidsmap
Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option - Aidsmap

Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option Aidsmap
Home tests aren’t an accurate way for people on HIV treatment to check they still have HIV - Aidsmap

Home tests aren’t an accurate way for people on HIV treatment to check they still have HIV Aidsmap
Long-acting injectable treatment highly effective in European cohort studies - Aidsmap

Long-acting injectable treatment highly effective in European cohort studies Aidsmap
Recycling tenofovir better than switch to second-line zidovudine - Aidsmap

Recycling tenofovir better than switch to second-line zidovudine Aidsmap
Immune modulator clears pre-cancerous anal lesions - Aidsmap

Antiretroviral drug levels in hair strongly predict viral suppression - Aidsmap

Antiretroviral drug levels in hair strongly predict viral suppression Aidsmap
Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years - A...

Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years Aidsmap
Doravirine/islatravir just as effective as Biktarvy in previously untreated people - Aidsmap

Doravirine/islatravir just as effective as Biktarvy in previously untreated people Aidsmap
Bictegravir safe and effective in pregnancy - Aidsmap

Adolescent-centred interventions lead to a 30-percentage-point increase in viral suppression in N...

Co-administration of dolutegravir-based treatment and short course of rifapentine/isoniazid (3HP)...

Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence o...

COVID-19 pandemic has speeded up the implementation of multi-month dispensing - Aidsmap

COVID-19 pandemic has speeded up the implementation of multi-month dispensing Aidsmap
Switching to Biktarvy maintains viral suppression in people aged 65 or over - Aidsmap

Switching to Biktarvy maintains viral suppression in people aged 65 or over Aidsmap
Tenofovir (TDF) does not increase risk of kidney disease in people at low risk - Aidsmap

Tenofovir (TDF) does not increase risk of kidney disease in people at low risk Aidsmap
Hepatitis C virtually eliminated in people with HIV in the Netherlands - Aidsmap

Hepatitis C virtually eliminated in people with HIV in the Netherlands Aidsmap
Viral suppression in Uganda improved by more viral load tests, done faster - Aidsmap

Viral suppression in Uganda improved by more viral load tests, done faster Aidsmap
Diagnosis and treatment for high blood pressure need to be funded as part of HIV treatment progra...

Fact check: COVID-19 is not a seasonal flu - Reuters

ヘンリー英王子とエルトン・ジョン、男性のエイズ対策で連携 - Reuters

ヘンリー英王子とエルトン・ジョン、男性のエイズ対策で連携 Reuters